arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Spero Therapeutics, Inc.

SPRO
$1.27 ▲ +0.01 (+0.79%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
45 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Bullish
auto_awesome

Analytical Summary

Spero Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $72.7M
Dividend Yield
Revenue Growth -95.6%
Op. Margin None
ROIC -11.2%
FCF / Share $0.28
Trailing P/E
Price / Book 1.4x
FCF Yield 21.8%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

45-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$258.00K
↓ -95.6%
Net Income Profit after all expenses
$-7.20M
↑ +48.1%
Operating Margin Operating profit as % of sales
76.0%
↑ +152.3% 55th
FCF / Share Free cash flow per share
$0.28
↓ -10.5%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
45
Returns
79
Cash Quality
8

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 45 quarters